Beam Therapeutics Inc Forecast, price target & analysts
Beam Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Beam Therapeutics Inc Classifications & Recommendation:
Beam Therapeutics Inc Price Target
| Target Price | $41.82 |
| Price | $16.80 |
| Potential |
148.93%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Beam Therapeutics Inc 2026 .
The average Beam Therapeutics Inc target price is $41.82.
This is
148.93%
register free of charge
$84.00
400.00%
register free of charge
$20.20
20.24%
register free of charge
|
|
| A rating was issued by 23 analysts: 19 Analysts recommend Beam Therapeutics Inc to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2026 of
148.93%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 63.52 | 53.22 |
| 83.18% | 16.21% | |
| EBITDA Margin | -619.71% | -889.55% |
| 1,395.95% | 43.54% | |
| Net Margin | -593.10% | -891.90% |
| 1,590.35% | 50.38% |
18 Analysts have issued a sales forecast Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2025. The average Beam Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Beam Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Beam Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.58 | -4.72 |
| 166.28% | 3.06% | |
| P/E | negative | |
| EV/Sales | 8.82 |
19 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Beam Therapeutics Inc...
Current Beam Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 10 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
